Stock Ratings / Health Care / XBIO / dividends

APUS (43) ADXN (57) CANF (31) PULM (36) ⌘ Pro Terminal →

Xenetic Biosciences Inc. (XBIO) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.12 +0.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Xenetic Biosciences Inc. (XBIO) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $5.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-4.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XBIO)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (12.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $31,901

Est. Year-10 Shareholder Yield: $574/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.2K

Yr 1

$12.6K

Yr 2

$14.2K

Yr 3

$15.9K

Yr 4

$17.9K

Yr 5

$20.1K

Yr 6

$22.5K

Yr 7

$25.3K

Yr 8

$28.4K

Yr 9

$31.9K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XBIO)

✓Walkthrough of XBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.03%📐 HORIZONTAL RANGE

2026-10-30O $2.14H $2.15L $1.95C $2.12VOL 32.6K

RES: $5.74SUP: $1.54SMA50: $2.85SMA200: $2.84

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XBIO Butterfly Map → + Track XBIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +19.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XBIO)

Health Care Rank #430 of 1016 ⚔️ APUS vs XBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XBIO vs. APUS, ADXN, CANF, PULM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Xenetic Biosciences Inc. (XBIO) ranks #430 by composite RQD confidence (47/100, grade D) and #948 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, XBIO leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. ADXN currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with XBIO at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XBIO ACTIVE Xenetic Biosciences Inc.	D	47/100	—	—	-30.3%	+0.95%	$5.0M	Benchmark Subject
APUS Apimeds Pharmaceuticals US Inc.	D-	43/100	—	—	-6.2%	+4.56%	$5.0M	/apus-vs-xbio →
ADXN Addex Therapeutics Ltd	D+	57/100	—	—	—	-1.01%	$5.0M	/adxn-vs-xbio →
CANF Can-Fite Biopharma Ltd each representing two (2)	E	31/100	—	—	-35.0%	+0.61%	$5.0M	/canf-vs-xbio →
PULM Pulmatrix Inc.	D-	36/100	—	—	-35.0%	-5.67%	$5.2M	/pulm-vs-xbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001534525

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xenetic Biosciences Inc. (XBIO) reported GAAP revenue of $3.0M (+19.0% vs. FY2024 revenue of $2.5M , and +17.2% cumulative change since FY2023) , GAAP net income of -$2.7M, operating cash flow of -$2.3M, and free cash flow of -$2.3M (+18.8% YoY). On the balance sheet, XBIO closed FY2025 with $8.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.0M	-$2.7M	-$2.3M	-$2.3M	$8.4M	—
FY2024 (FY)	2024-12-31	$2.5M	-$4.0M	-$2.8M	-$2.8M	$6.9M	—
FY2023 (FY)	2023-12-31	$2.5M	-$4.1M	-$4.1M	-$4.1M	—	—

3. XBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Xenetic Biosciences Inc. (NASDAQ: XBIO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $2.12 (+0.95% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, XBIO ranks #430 in composite RQD confidence.

How does XBIO compare to APUS and ADXN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.3%. By comparison, APUS (Apimeds Pharmaceuticals US Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -6.2%, cap $5.0M) and ADXN (Addex Therapeutics Ltd) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $5.0M). Among the 5-stock peer group, XBIO leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XBIO?

Per XBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534525), Xenetic Biosciences Inc. generated $3.0M in revenue (+19.0% YoY), -$2.7M in net income, and -$2.3M in free cash flow against $8.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

XBIO last traded at $2.12 (+0.95% on volume of 34,454 shares), positioning the stock -25.61% below its 50-day simple moving average ($2.85) and -25.35% below its 200-day simple moving average ($2.84). Across its 52-week range of $1.58 to $4.94, XBIO sits at the 16.1% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.85 to $2.39).

XBIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does XBIO pay a dividend and is it safe?

Xenetic Biosciences Inc. (XBIO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: XBIO RQD Cockpit XBIO 12M Forecast XBIO Earnings & Move XBIO Dividends & DRIP XBIO Insiders & 13F XBIO Whale Options XBIO Profit Sankey XBIO News & Why